Last reviewed · How we verify
Suvemcitug injection, trifluridine/tipiracil tablets
Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells.
Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells. Used for Metastatic colorectal cancer (previously treated), Gastric cancer (advanced or metastatic).
At a glance
| Generic name | Suvemcitug injection, trifluridine/tipiracil tablets |
|---|---|
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Drug class | Nucleoside analog; antimetabolite |
| Target | Thymidylate synthase; DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trifluridine is a thymidine-based nucleoside analog that is incorporated into DNA and inhibits thymidylate synthase, disrupting DNA synthesis. Tipiracil is a thymidine phosphorylase inhibitor that enhances trifluridine bioavailability by preventing its degradation. Together, they increase intracellular trifluridine concentrations, leading to DNA damage and cancer cell death.
Approved indications
- Metastatic colorectal cancer (previously treated)
- Gastric cancer (advanced or metastatic)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: